NICE drafts scope for Genzyme/Isis' Kynamro
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has released a draft scope for consultation of Genzyme/Isis Pharmaceuticals ' Kynamro (mipomersen sodium) for hypercholesterolaemia.